Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 16/20 | 0.58 |
| ▸ | JAK3 | P52333 | 16/20 | 0.58 |
| ▸ | JAK2 | O60674 | 8/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL524527 | 1.00 | JAK1 (0.58) | JAK1JAK3JAK2CYP3A4AURKA | |
| SCHEMBL23356154 | 0.97 | JAK1 (0.62) | JAK1JAK3JAK2CYP3A4AURKA | |
| SCHEMBL341426 | 0.89 | JAK1 (0.70) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| Formic Acid SCHEMBL29358792 | 0.88 | AURKA (0.62) | JAK1JAK3JAK2CYP3A4AURKA | |
| Formic Acid SCHEMBL524267 | 0.88 | AURKA (0.62) | JAK1JAK3JAK2CYP3A4AURKA | |
| Formic Acid SCHEMBL525312 | 0.87 | JAK1 (0.59) | JAK1JAK3JAK2CYP3A4AURKA | |
| Formic Acid SCHEMBL29358016 | 0.87 | JAK1 (0.59) | JAK1JAK3JAK2CYP3A4AURKA | |
| SCHEMBL341185 | 0.86 | JAK1 (0.68) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL29610076 | 0.86 | JAK1 (0.68) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| Formic Acid SCHEMBL29358508 | 0.85 | JAK1 (0.55) | JAK1JAK3JAK2CYP3A4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.